Member Info for ShearClass

Well worth watching the results presentation if any of existing / prospective investors haven't already;

https://www.lcmfinance.com/shareholders/full-year-results-webcast/

They are EXTREMELY bullish on the future prospects, the last comment from Patrick is in relation to achieving £1b market cap in the next 5-10 years, to which he responds that he'd like to think they can do it sooner...

They also clarify that any further funding will be derived from debt + a profit share equity element, so there will be no dilution, which you can trust when the CEO owns just shy of 8% of the company.

Also we can expect them to announce their second third party fund in the next few months, they are aiming for around $350m this time, so significantly larger than the first.

It took BUR 4 years from IPO in 2010 to break out, then there was no stopping it. When LIT announces their second larger third party fund, followed by the third, they will start to gain some serious traction IMO. Certainly from £60m market cap I can’t see any downside...

It's an interesting one, the directors will still own 37% of the business once the DBAY sale has completed, so it's not a given they will sell the rest at this level... However, it does show a lack of ambition to sell nearly a third of the company at 25% below the pre Covid high. I've taken a small profit from my purchase earlier this week and will reinvest them somewhere a tad more exciting...

This is ideally primed for the santa run, a positive update on the AZN collab could see a run towards 10p IMO, just look at IQAI

RHT99, I take it that you can't read?

- They raised £2.1m in July to add to the £2m that was on the balance sheet at 30th June (as per the half year report on 10th September). So had around £4m of cash at the end of July.

- Losses for the half year to 30th June decreased to £1.17m, so cash would last just shy of 2 years at this burn rate.

- However, revenues are increasing significantly (each ICSYNTH license brings in between €50-100k per annum, so the 5 recently signed deals add between of £200-400k per annum).

Bottom line - they don't need cash, and if ICSYTH licenses keep coming in at the present rate they'll be at breakeven very soon, and that is ignoring progress on DigitalGlassware with Novartis / AZN.

I hope you're short as you'll get rogered when the next big RNS lands.

Have to laugh at DP, can only be a market maker or someone who has a hidden agenda to be spouting such utter rubbish. It ain’t working mate, the co-morbidities were evenly split between placebo & SNG001, a 5 year old could read that. They only displayed the diabetes & cardiovascular disease breakdown, does that mean cancer, CKD et al don’t count? On the filter list, I was suggest everyone else does the same.

I've no idea what anyone sees in TILS at the current valuation of £232m market cap ex Stemprinter spin off...

They were trading 37p (£56m market cap) on the day before they announced their potential Covid treatment and that included Stemprinter. Now that is gone, you are effectively paying a 200% premium for a potential Covid treatment with no evidence of efficacy. I know they have other drugs, but none have commenced P2 so aren't of any material value yet.

If their Covid trial doesn't produce a statistically significant result the share price is going to fall off a cliff IMO, I think this is what is being reflected in the current fall.

You can do a Bed & ISA transaction on HL and set it up so that the shares you are selling in the fund account are automatically rebought in your ISA. You lose a bit due to the spread, and risk that if it's timed badly on a volatile share like SNG that you could lose more than a bit. Normally completed quickly, but I'd imagine if you called them up they would do it whilst you were on the phone. Certainly no need to be out of the market for 2 days, especially with the potential newsflow!

Great to get the placing completed, they are really well set now. I think we'll see at least two pieces of significant newsflow before the Sharesoc webinar on 18th November, my expectation would be peer review + official launch of the P3 trial.

There are many other left field items that could arrive through now that we are fully financed. Worth re listening to the below interview with RM on 21st October where he talks about partnering discussions, stating that 'we're running a process & we've got some advisors helping us with that'. I'd hazard a guess that the advisor is Numis, and we know the calibre of deal that they are capable of putting together. He also states that they ultimately want to partner with a large pharma co. Any news along these lines would certainly make things interesting!

https://www.youtube.com/watch?v=BFFo7fhk-zM&feature=youtu.be

False drop of bid to 38p and NT to buy - a matter of time before a nice bounce here IMO

Madness to fall 50% on a 10% drop in sales, you'd think they had reported the who sales pipeline had cancelled...!

I'm not sure that 30 day rule applies on AIM, however in this case she wouldn't necessarily be an insider having subscribed for shares prior to joining the company. She also paid well above market rate which is unusual, perhaps this was to emphasise it was an arms length transaction.

My expectation is we'll get a big RNS between now and the end of the year, which will either be an update on the AZN collaboration (the 1 year anniversary of it's announcement will be in December) or the announcement of the new collaboration with Novartis. Of course something left field could arrive, but the above two would be favourites IMO.

Yes I thought that was a ridiculous response from JAdam, it is a complex company, hence why it's under the radar.

In simple terms DeepMatter were formally called Cronin Group, having bought Cronin 3D for £5m back in 2015. DeepMatter own the trademark to the Chemputer, but the CNBC article posted over the weekend references work done by Lee Cronin's new entity, Chemify. So DeepMatter aren't linked directly to GSK at present, if they were there would have been an RNS!

However, DeepMatter do have ongoing collaborations / assessments underway with big pharma to assess DigitalGlassware, which is to my understanding the early Chemputer work done by Cronin which allows systematic recording, coding & sharing of chemistry data in the cloud. The Astra collaboration announced last December is the most significant to date, and a Novartis collaboration was mentioned in the July placing as being in the process of being finalised. News from either of these two will instantly double the share price I'd imagine.

My take away from the CNBC article would be that the new Chemputer work being undertake by Cronin flags his brilliance & adds renewed credibility to DeepMatter, increasing the likelihood of AZN / Novartis / other big pharma signing long terms deals for DigitalGlassware etc. You'd also have to think that if Lee Cronin wanted to capitalise on the new work done by Chemify there is half a chance that DMTR could acquire them in a similar way to their Cronin 3D acquisition.

An interesting company for sure, and one I'm happy to have in my portfolio at the current valuation. DeepVerge is certainly a comparable in that it's an AI focused life sciences company, post it's Modern Water merger it'll be valued at around £50m, which is almost 3 x DMTR. Additionally DeepVerge don't have relationships with AZN or big pharma, which makes the risk reward here even better IMO.

That's over 4% of the company in 1 trade... this feels like a tinderbox at £7m market cap

Probably someone gone short, not my game but this was as obvious as they come from the 8p range, particularly when they started exercising warrants... Daylight robbery to price the IPO where they did.

Indeed they are, the seller won't last much longer with volume like this...

Guys, the reason this is plummeting is because it’s become the 14th most shorted stock on LSE... 7 hedgies are short by a combined 6.77% with most increasing substantially this month.

What do they know to make them all so confident?

https://*********************/ShortInterestTracker/CompanyData?companyId=GB00BH3VJ782&viewOnMobile=True

https://arrival.com/

https://arrival.com/news/arrival-accelerates-global-expansion-with-118m-investment

"Arrival, the technology company focused on commercial electric vehicles announced it has raised $118 million from funds managed by BlackRock. The fundraising will be used to support execution of the company’s growth plans as it ramps up vehicle production, including the launch of Arrival’s first U.S. Microfactory in South Carolina."

Expected pull back today after last weeks strong rise, but it didn't get very far...

@Crecendo, if you held RENX shares on 9th July you should have received 1 x Verici share for every RENX share. So if you had 1000 RENX shares at that date, you will now have 1000 x Verici shares. It doesn't matter how many RENX shares you now hold.

You have until 12 noon tomorrow to decide whether you want to apply for additional Verici shares at 20p per share in the open offer. If you apply for more shares, they will be incremental to the ones received as part of the dividend in specie. It's all explained in the RNS / Circular.

Positive to read the news re. Kantaro today, and see NASDAQ break out of a downtrend - hopefully the start of a rise back towards the year highs - it makes little sense to be nearly 30% below them.

The circa £750k BTC purchase by Mode is not significant versus their £40m market cap, even if BTC hit $100k, their holding would only be a fifth of their current cap... Compare that to KR1's Polkadot holding of 3.5m DOT worth £11.6m at current prices vs the KR1 market cap of £18m and the difference is stark.

Re. a big holder trashing the price, why would they? You may as well say a hedgie could take a huge short out against Mode Global...

@EGTP,
Quote from the Sun article you shared;

“Students at De Montford and Durham universities are already using them, as well as children at three schools in the South.”

No chance this is the AVCT test, if it was they would have RNS’d the above and ramped up the share price further, so Dr Smith could buy a bigger house...!

Competition is fierce now, if they had been able to release the test in mid summer then who knows where the SP would be (and what size house the CEO could have bought).